Exp Clin Endocrinol Diabetes 2008; 116(9): 541-548
DOI: 10.1055/s-2008-1062728
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Enhanced Immunogenicity of Peptide P277 by Heat Shock Protein HSP65 Vector Carrying Tandem Repeats of P277 to Prevent Type 1 Diabetes in NOD Mice

J. Liang 1 , Z. Aihua 2 , W. Yu 1 , L. Jingjing 1
  • 1Minigene Pharmacy Laboratory, Biopharmaceutical College, China Pharmaceutical University, Nanjing, PR China
  • 2Key Laboratory of Biotechnology for Medicinal Plants of Jinangsu Province, Xuzhou Normal University, PR China
Further Information

Publication History

received 29.10.2007 first decision 24.01.2008

accepted 13.02.2008

Publication Date:
13 May 2008 (online)

Abstract

The peptide P277 contains a target epitope for diabetogenic T cells and it has been used as an ideal target antigen to develop vaccines against type 1 diabetes. A major problem in developing P277 vaccine is its low immunogenicity. Recent applications involving multiple copies of self-peptide in linear alignment and conjugation with carrier proteins appear to increase the immune response. In this study, we designed a method based on isocaudamer technique to repeat tandemly the 24-residue sequence P277, then 6 tandemly repeated copies of the peptide P277 were fused to mycobacterial heat-shock protein 65 to construct a fusion protein HSP65-6×P277 as an immunogen. We examined the effect of the tandem repeats of the peptide P277 in eliciting an immune response by comparing the immunogenicity of the three immunogens: P277, HSP65-P277 and HSP65-6×P277. Immunization of mice with the fusion protein HSP65-6×P277 elicited much higher levels of specific anti-P277 antibodies than with P277 and HSP65-P277, which should suggest that multiple tandem repeats of a certain epitope is an efficient method to overcome the low immunogenicity of self-peptide antigens and the immunogen HSP65-6×P277 might be further developed to a vaccine against type 1 diabetes.

References

  • 1 Anjam CM, Villarreal-Ramos B, Pierce RJ, Demarco de Hormaeche R, MacNeill H, Ali T, Chatfield S, Capron A, Dougan G, Hormaeche CE. Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma Mansoni peptide 115-131 of the P22 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live Aro-attenuated vaccine strain of Salmonella.  J Immunol. 1994;  153 5634
  • 2 Barrios C, Lussow AR, Embden J Van, Zee R Van der, Rappuoli R, Costantino P. et al . Mycobacterial heat shock proteins as carrier molecules. The use of the 70-kDa mycobacterial heat shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming.  Eur J Immunol. 1992;  22 1365
  • 3 Barrios C, Tougne C, Polla BS, Lambert PH, Del GG. Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kDa.  Clin Exp Immunol. 1994;  98 224
  • 4 Birk OS, Douek DC, Elias D, Takacs K, Dewchand H, Gur SL, Walker MD, Zee R van der, Cohen IR, Altmann DM. A role of Hsp60 in autoimmune diabetes: analysis in a transgenic model.  Proc Natl Acad Sci USA. 1996;  93 1032
  • 5 Bougneres PF. et al . Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin.  Diabetes. 1990;  39 1264
  • 6 Cohen IR. Peptide therapy for type 1 diabetes: the immunological homunculus and the rationale for vaccination.  Diabetologia. 2002;  45 1468
  • 7 Daneman D. Type 1 diabetes.  Lancet. 2006;  367 847
  • 8 Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice.  Lancet. 1994;  343 704
  • 9 Elias D, Markovits D, Reshef T, Zee R Van der, Cohen IR. Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein.  Proc Natl Acad Sci USA. 1990;  87 1576
  • 10 Elias D, Reshef T, Birk OS, Zee R van der, Walker MD, Cohen IR. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein.  Proc Natl Acad Sci USA. 1991;  88 3088
  • 11 Gaofu Q, Jun L, Xiuyun Z, Wentao L, Jie W, Jingjing L. Long lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants.  Vaccine. 2004;  22 3187
  • 12 Hannesdottir SG, Han X, Lund T, Singh M, Zee R van der, Roitt IM. et al . Changes in the reproductive system of male mice immunized with a GnRH-analogue conjugated to mycobacterial hsp70.  Reproduction. 2004;  128 365
  • 13 Hsu CT, Ting CY, Ting CJ, Chen TY, Lin CP, Whang-Peng J, Hwang J. Vaccination against gonadotropin-releasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats.  Cancer Res. 2000;  60 3701
  • 14 Jingjing L, Xue Y, Agarwal N, Roque RS. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor.  Invest Ophthalmol Vis Sci. 1999;  40 752
  • 15 Jinshu X, Jingjing L, Duana P, Zheng Z, Ding M, Jie W, Rongyue C, Zhuoyi H, Rouel SR. A synthetic gonadotropin-releasing hormone (GnRH) vaccine for control of fertility and hormone dependent diseases without any adjuvant.  Vaccine. 2005;  23 4834
  • 16 Kelly MA, Rayner ML, Mijovic CH, Barnett AH. Molecular aspects of type 1 diabetes.  J Clin Pathol. 2003;  56 1-10
  • 17 Kim HD, Maxwell JA, Kong FK, Tang DC, Fukuchi K. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of A b1–6: toward safer and effective vaccines against Alzheimer's disease, Biochem.  Biophys Res Commun. 2005;  336 84
  • 18 Maron R, Sukhova G, Faria AM, Hoffmann E, Mach F, Libby P, Weiner HL. Mucosal administration of hsp65 decreases atherosclerosis and inflammation in Aortic Arch of low-density lipoprotein receptor-deficient mice.  Circulation. 2002;  106 1708
  • 19 Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.  Clin Cancer Res. 2002;  8 2044
  • 20 Oscherwitz J, Zeigler ME, Loh CJ, Gribbin TE, Cease KB. The enhanced immunogenicity of a recombinant immunogen containing a tandemly repeated HIV-1 T helper epitope is an intrinsic immunological property unrelated to epitope dose.  Vaccine Res. 1997;  6 15
  • 21 Palliser D, Huang Q, Hacohen N, Lamontagne SP, Guillen E, Young RA, Eisen HN. A role for Toll-like receptor 4 in dendritic cell activation and cytolytic CD8+ T cell differentiation in response to a recombinant heat shock fusion protein.  J Immunol. 2004;  172 2885
  • 22 Perraut R, Lussow AR, Gavoille S, Garrard O, Matile H, Tougne C. et al . Successful primate immunization with peptides conjugated in the absence of adjuvants.  Clin Ezp Immunol. 1993;  93 382
  • 23 Romero SS, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE. et al . Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity.  Clin Infect Dis. 1999;  29 281
  • 24 Silverstein J. et al . Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus.  N Engl J Med. 1988;  319 599
  • 25 Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity.  Nat Rev Immunol. 2002;  2 185
  • 26 Suzue K, Zhou X, Eisen HN, Young RA. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway.  Proc Natl Acad Sci USA. 1997;  94 13146
  • 27 Tobian AAR, Canaday DH, Harding CV. Bacterial heat shock proteins enhance class II MHC antigen processing and presentation of chaperoned peptides to CD4+ T cells.  J Immunol. 2004;  173 5130
  • 28 Tobian AAR, Harding CV, Canaday DH. Mycobacterium tuberculosis heat shock fusion protein enhances class I MHC crossprocessing and -presentation by B lymphocytes.  J Immunol. 2005;  174 5209
  • 29 Yankai Z, Rong Y, Yi H, Wentao L, Rongyue C, Ming Y, Taiming L, Jingjing L, Jie W. Ten tandem repeats of β-hCG 109–118 enhance immunogenicity and anti-tumor effects of β-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.  Biochemical and Biophysical Research Communications. 2006;  345 1365
  • 30 Yi H, Rong Y, Yankai Z, Wentao L, Hongxia Z, Jie W, Rongyue C, Taiming L, Jingjing L. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.  Vaccine. 2006;  24 2575

Correspondence

L. Jingjing

Minigene Pharmacy Laboratory

Biopharmaceutical College

China Pharmaceutical University

Tongjia Xiang 24

Nanjing

210009

PR China

Phone: +86/25/83 27 12 42

Fax: +86/25/83 20 42 40

Email: minigene1@yahoo.com.cn